BOT botanix pharmaceuticals ltd

Current And Future Valuation 2025, page-193

  1. 3,060 Posts.
    lightbulb Created with Sketch. 524
    What’s got me thinking is the crazy SOI the CRs have caused.

    Im only thinking this because DXB pathway to revenue is through licensing deals, which attract upfront payments and diminish the need for a CR.

    But then how attractive would BOT (in particularly Sofdra) be if revenues were tied to other companies?

    Is this the biggest indicator as to takeover being the endgame? Thoughts?

    I could be completely wrong so don’t cuss me out to much.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
30.0¢
Change
0.000(0.00%)
Mkt cap ! $588.2M
Open High Low Value Volume
30.5¢ 31.0¢ 30.0¢ $2.131M 7.020M

Buyers (Bids)

No. Vol. Price($)
18 504695 30.0¢
 

Sellers (Offers)

Price($) Vol. No.
30.5¢ 38124 3
View Market Depth
Last trade - 16.10pm 24/06/2025 (20 minute delay) ?
BOT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.